182 related articles for article (PubMed ID: 14569841)
21. Irinotecan in esophageal cancer.
Enzinger PC; Ilson DH
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):26-30. PubMed ID: 11200145
[TBL] [Abstract][Full Text] [Related]
22. 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
Kindler HL; Avadhani A; Wade-Oliver K; Karrison T; Mani S; Vokes EE
Invest New Drugs; 2004 Aug; 22(3):323-7. PubMed ID: 15122080
[TBL] [Abstract][Full Text] [Related]
23. Irinotecan/thalidomide in metastatic colorectal cancer.
Govindarajan R
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):23-6. PubMed ID: 12014864
[TBL] [Abstract][Full Text] [Related]
24. The activity of paclitaxel in gastrointestinal tumors.
Ajani JA; Ilson DH; Kelsen DP
Semin Oncol; 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PubMed ID: 7481861
[TBL] [Abstract][Full Text] [Related]
25. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Lustberg MB; Bekaii-Saab T; Young D; Otterson G; Burak W; Abbas A; McCracken-Bussa B; Lustberg ME; Villalona-Calero MA
J Thorac Oncol; 2010 May; 5(5):713-8. PubMed ID: 20354452
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group.
Armanios M; Xu R; Forastiere AA; Haller DG; Kugler JW; Benson AB;
J Clin Oncol; 2004 Nov; 22(22):4495-9. PubMed ID: 15542799
[TBL] [Abstract][Full Text] [Related]
27. Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: a case report.
Takahashi N; Suzuki H; Iwabuchi S; Yamazaki Y; Yanaga K
Hepatogastroenterology; 2005; 52(61):326-8. PubMed ID: 15783061
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.
Katsube T; Ogawa K; Ichikawa W; Fujii M; Tokunaga A; Takagi Y; Kochi M; Hayashi K; Kubota T; Aiba K; Arai K; Terashima M; Kitajima M
Anticancer Drugs; 2007 Jun; 18(5):605-10. PubMed ID: 17414630
[TBL] [Abstract][Full Text] [Related]
29. [Irinotecan (CPT-11) therapy for advanced gastric cancer].
Sakata Y
Nihon Rinsho; 2001 Apr; 59 Suppl 4():386-92. PubMed ID: 11424411
[No Abstract] [Full Text] [Related]
30. Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
Koutras AK; Gerolymos MK; Kontogeorgou E; Iconomou G; Vourli G; Tsiata E; Makatsoris T; Chrysanthopoulos C; Kalofonos HP
J Chemother; 2007 Dec; 19(6):724-30. PubMed ID: 18230557
[TBL] [Abstract][Full Text] [Related]
31. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
[TBL] [Abstract][Full Text] [Related]
32. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma.
Ajani JA; Baker J; Pisters PW; Ho L; Feig B; Mansfield PF
Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):52-4. PubMed ID: 11301842
[TBL] [Abstract][Full Text] [Related]
33. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan in esophageal cancer.
Ilson DH; Minsky B
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):32-6. PubMed ID: 14569846
[TBL] [Abstract][Full Text] [Related]
35. The emerging world role of irinotecan in lung cancer.
Langer CJ
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors.
Komaki R; Janjan NA; Ajani JA; Lynch PM; Fairweather JS; Raijman I; Blumenshein GR; Ho L; Pisters PW; Feig BW; Walsh GL; Pazdur R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):34-7. PubMed ID: 11200147
[TBL] [Abstract][Full Text] [Related]
37. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
38. [Alternatives to surgical treatment of adenocarcinomas of the esophagus and the cardia].
Seitz JF
Gastroenterol Clin Biol; 1994; 18(1 Pt 2):D67-70. PubMed ID: 8013789
[No Abstract] [Full Text] [Related]
39. [Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Seitz JF; Duffaud F; Dahan L; Ries P; Ville E; Laugier R
Cancer Radiother; 2001 Nov; 5 Suppl 1():107s-112s. PubMed ID: 11797269
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma.
Smyth EC; Petty RD
Lancet; 2018 Jul; 392(10142):97-98. PubMed ID: 29880232
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
